Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
Type
Guidance (302)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (302)
Apply filters
Showing 51 to 100 of 302
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Technology appraisal guidance
TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
Technology appraisal guidance
TBC
Cladribine for treating relapsing multiple sclerosis ID6263
Technology appraisal guidance
5 February 2025
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]
Technology appraisal guidance
TBC
Colon cancer (adjuvant) - irinotecan [ID379]
Technology appraisal guidance
TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Technology appraisal guidance
TBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]
Technology appraisal guidance
16 October 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]
Technology appraisal guidance
30 October 2024
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]
Technology appraisal guidance
11 September 2024
Dapagliflozin for treating chronic kidney disease [ID6411]
Technology appraisal guidance
12 February 2025
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Technology appraisal guidance
TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
28 July 2021
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Technology appraisal guidance
TBC
DCVax-L for treating glioblastoma [ID836]
Technology appraisal guidance
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID 3897
Technology appraisal guidance
TBC
Diabetic retinopathy - ruboxistaurin [ID382]
Technology appraisal guidance
TBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
Technology appraisal guidance
11 September 2024
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Technology appraisal guidance
TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
Technology appraisal guidance
TBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235
Technology appraisal guidance
TBC
Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]
Technology appraisal guidance
TBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Technology appraisal guidance
TBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Technology appraisal guidance
TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317
Technology appraisal guidance
TBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725
Technology appraisal guidance
TBC
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Technology appraisal guidance
TBC
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
Technology appraisal guidance
TBC
Efgartigimod for treating generalised myasthenia gravis [ID4003]
Technology appraisal guidance
TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Technology appraisal guidance
TBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]
Technology appraisal guidance
TBC
Elafibranor for treating primary biliary cholangitis [ID6331]
Technology appraisal guidance
TBC
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]
Technology appraisal guidance
5 June 2024
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]
Technology appraisal guidance
TBC
Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer ID6177
Technology appraisal guidance
TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Technology appraisal guidance
15 June 2022
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]
Technology appraisal guidance
14 August 2024
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
Technology appraisal guidance
TBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]
Technology appraisal guidance
TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
Technology appraisal guidance
29 January 2025
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]
Technology appraisal guidance
TBC
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]
Technology appraisal guidance
11 September 2024
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
Technology appraisal guidance
TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
Technology appraisal guidance
TBC
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]
Technology appraisal guidance
TBC
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]
Technology appraisal guidance
14 August 2024
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]
Technology appraisal guidance
16 October 2024
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]
Technology appraisal guidance
22 May 2024
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]
Technology appraisal guidance
TBC
Previous page
1
Current page
2
3
4
…
7
Page
2
of
7
Next page
Results per page
10
25
50
All
Back to top